NCT03242278View on ClinicalTrials.gov

Real-world Dosing Patterns of Rivaroxaban in the United States

CompletedOBSERVATIONAL

Enrollment

12,507

Participants

Timeline

Start Date

February 12, 2016

Primary Completion Date

March 1, 2016

Study Completion Date

March 1, 2016

Conditions

Atrial Fibrillation

Interventions

DRUG

Rivaroxaban (Xarelto, BAY59-7939)

As prescribed by treating physicians

Trial Locations (1)

Unknown

New York

Sponsors

Lead Sponsor

All Listed Sponsors

collaborator

Janssen Research & Development, LLC

INDUSTRY

lead

Bayer

INDUSTRY